El Kassas M, et al. - Researchers performed a prospective follow-up study including hepatitis B virus (HBV) surface antigen (HBsAg)-positive Egyptians undergoing interferon-free direct-acting antivirals (DAAs), to estimate the risk of HBV reactivation and HBV-related hepatitis. A meta-analysis was also performed to determine the reactivation risk using published data obtained from a systematic review of PubMed/Embase, in addition to the Egyptian data. Findings confirmed a high HBV reactivation risk in HBsAg-positive patients undergoing DAAs, with only a minority developing clinically important hepatitis. In HBsAg-negative antibody to HBV core antigen-positive patients, the risk was negligible.